MEI Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . MEI Pharma
MEIP Stock  USD 2.70  0.10  3.57%   
MEI Pharma financial statements provide useful quarterly and yearly information to potential MEI Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on MEI Pharma financial statements helps investors assess MEI Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting MEI Pharma's valuation are summarized below:
Gross Profit
48.8 M
Profit Margin
0.2723
Market Capitalization
18 M
Enterprise Value Revenue
1.3924
Revenue
65.3 M
There are currently one hundred twenty fundamental ratios for MEI Pharma that can be evaluated and compared over time across peers in the industry. Investors and active traders are advised to check MEI Pharma's last-minute fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction. As of 12/15/2024, Market Cap is likely to grow to about 154.3 M. Also, Enterprise Value is likely to grow to about 141.7 M

MEI Pharma Total Revenue

68.56 Million

Check MEI Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MEI Pharma's main balance sheet or income statement drivers, such as Interest Expense of 310.3 K, Selling General Administrative of 24.5 M or Total Revenue of 68.6 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.49 or PTB Ratio of 0.55. MEI financial statements analysis is a perfect complement when working with MEI Pharma Valuation or Volatility modules.
  
Check out the analysis of MEI Pharma Correlation against competitors.
To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.

MEI Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets62.7 M41.4 M82.9 M
Slightly volatile
Other Current Liabilities3.9 M5.2 M4.6 M
Slightly volatile
Total Current Liabilities8.3 M8.4 M10.7 M
Slightly volatile
Total Stockholder Equity32.7 M33 M40.4 M
Pretty Stable
Accounts Payable2.2 M3.2 M2.8 M
Slightly volatile
Cash3.5 M3.7 M12.4 M
Slightly volatile
Cash And Short Term Investments57.3 M38.3 M75.1 M
Slightly volatile
Common Stock Shares Outstanding7 M6.7 M3.3 M
Slightly volatile
Liabilities And Stockholders Equity62.7 M41.4 M82.9 M
Slightly volatile
Other Current Assets1.9 M2.4 M2.7 M
Slightly volatile
Other Stockholder Equity442.3 M421.2 M269.5 M
Slightly volatile
Total Liabilities7.9 M8.4 M41 M
Slightly volatile
Total Current Assets60.9 M40.8 M80.2 M
Slightly volatile
Short and Long Term Debt Total15.4 M14.6 M9.1 M
Slightly volatile
Property Plant And Equipment Net575.7 K606 K2.4 M
Slightly volatile
Non Current Assets Total575.7 K606 K2.6 M
Slightly volatile
Property Plant And Equipment Gross2.9 M2.4 M2.8 M
Slightly volatile
Property Plant Equipment16 M15.3 M4.4 M
Slightly volatile
Net Tangible Assets48.6 M28.3 M40.7 M
Slightly volatile
Capital Surpluse255 M424.5 M255 M
Slightly volatile
Current Deferred Revenue346.3 K364.6 K3.2 M
Pretty Stable
Net Invested Capital37.9 M33 M48.1 M
Slightly volatile
Net Working Capital30.8 M32.4 M75.4 M
Slightly volatile
Other Liabilities78.2 M74.2 M60.2 M
Slightly volatile
Net Receivables72.7 K76.5 K3.1 M
Pretty Stable
Non Current Liabilities Other26.8 M26.8 M38.1 M
Slightly volatile
Short Term Debt2.4 M3.3 M2 M
Slightly volatile

MEI Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative24.5 M23.3 M14.2 M
Slightly volatile
Other Operating Expenses32.7 M50.8 M42.5 M
Slightly volatile
Research Development20.2 M16.6 M26.8 M
Slightly volatile
Total Operating Expenses31.9 M50.8 M41.3 M
Slightly volatile
Selling And Marketing Expenses4.3 M2.3 M3 M
Slightly volatile
Interest Income3.4 M3.3 M1 M
Slightly volatile
Reconciled Depreciation234.7 K383 K163.4 K
Slightly volatile

MEI Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow3.5 M3.7 M12.4 M
Slightly volatile
Stock Based Compensation4 M2.3 M4.1 M
Slightly volatile
Depreciation402.1 K383 K156.8 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.280.290830.7597
Slightly volatile
Dividend Yield0.490.550.6015
Slightly volatile
PTB Ratio0.550.57512.9851
Slightly volatile
Days Sales Outstanding0.690.73251
Slightly volatile
Book Value Per Share4.714.955741.5729
Slightly volatile
Stock Based Compensation To Revenue0.03310.03490.3527
Very volatile
Capex To Depreciation0.01740.01831.615
Very volatile
PB Ratio0.550.57512.9851
Slightly volatile
EV To Sales0.220.234127.9317
Slightly volatile
Days Of Inventory On Hand1.0E-43.0E-42.0E-4
Slightly volatile
Payables Turnover0.110.12090.9193
Very volatile
Sales General And Administrative To Revenue0.340.35681.0431
Very volatile
Average Inventory0.40.450.49
Slightly volatile
Research And Ddevelopement To Revenue0.240.25362.6898
Pretty Stable
Capex To Revenue1.0E-41.0E-40.0139
Very volatile
Cash Per Share5.475.754954.0494
Slightly volatile
Payout Ratio0.530.590.6431
Slightly volatile
Days Payables Outstanding3.2 K3 K3.1 K
Slightly volatile
Intangibles To Total Assets0.00340.00360.0062
Slightly volatile
Current Ratio4.644.87968.6265
Slightly volatile
Tangible Book Value Per Share4.714.955741.4227
Slightly volatile
Receivables Turnover543517111
Slightly volatile
Graham Number16.3917.2485159
Slightly volatile
Shareholders Equity Per Share4.714.955741.5729
Slightly volatile
Debt To Equity0.05480.05220.0286
Slightly volatile
Capex Per Share0.0010.00110.0545
Very volatile
Graham Net Net4.284.50139.7039
Slightly volatile
Revenue Per Share10.299.79998.9592
Slightly volatile
Interest Debt Per Share0.470.250.717
Slightly volatile
Debt To Assets0.00590.01060.0061
Slightly volatile
Operating Cycle0.690.7341.9536
Pretty Stable
Price Book Value Ratio0.550.57512.9851
Slightly volatile
Days Of Payables Outstanding3.2 K3 K3.1 K
Slightly volatile
Dividend Payout Ratio0.530.590.6431
Slightly volatile
Ebt Per Ebit0.811.22250.9957
Very volatile
Company Equity Multiplier1.391.2531.9791
Slightly volatile
Total Debt To Capitalization0.02480.04930.0258
Slightly volatile
Debt Equity Ratio0.05480.05220.0286
Slightly volatile
Quick Ratio4.644.87968.6265
Slightly volatile
Net Income Per E B T1.091.151.0055
Pretty Stable
Cash Ratio0.420.44343.096
Slightly volatile
Days Of Inventory Outstanding1.0E-43.0E-42.0E-4
Slightly volatile
Days Of Sales Outstanding0.690.73251
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.81.00010.9879
Slightly volatile
Price To Book Ratio0.550.57512.9851
Slightly volatile
Fixed Asset Turnover94.11108238
Slightly volatile
Debt Ratio0.00590.01060.0061
Slightly volatile
Price Sales Ratio0.280.290830.7597
Slightly volatile
Asset Turnover1.661.57820.4512
Slightly volatile
Price Fair Value0.550.57512.9851
Slightly volatile

MEI Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap154.3 M146.9 M136.4 M
Slightly volatile
Enterprise Value141.7 M134.9 M123.1 M
Slightly volatile

MEI Fundamental Market Drivers

Cash And Short Term Investments38.3 M

MEI Upcoming Events

8th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
24th of September 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of June 2023
Last Financial Announcement
View

About MEI Pharma Financial Statements

MEI Pharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although MEI Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in MEI Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on MEI Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue364.6 K346.3 K
Total Revenue65.3 M68.6 M
Cost Of Revenue383 K363.9 K
Stock Based Compensation To Revenue 0.03  0.03 
Sales General And Administrative To Revenue 0.36  0.34 
Research And Ddevelopement To Revenue 0.25  0.24 
Revenue Per Share 9.80  10.29 
Ebit Per Revenue 0.22  0.23 

Pair Trading with MEI Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MEI Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MEI Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against MEI Stock

  0.55FLGC Flora Growth CorpPairCorr
  0.37DYAI Dyadic InternationalPairCorr
  0.35DNA Ginkgo Bioworks HoldingsPairCorr
  0.32ESPR Esperion TherapeuticsPairCorr
  0.32IMAB I MabPairCorr
The ability to find closely correlated positions to MEI Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MEI Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MEI Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MEI Pharma to buy it.
The correlation of MEI Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MEI Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MEI Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MEI Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for MEI Stock Analysis

When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY